e2e Pharma, a private label end-to-end manufacturer for CBD and non-CBD branded topicals and ingestibles that are sold direct to consumers online and through nationwide retail chains, is expanding the company’s fully operational, 30,000-square-foot manufacturing facility with four clean rooms and warehousing.
e2e’s GMP-certified manufacturing facility will help create 12-15 different white and private label form factors for brands, including topicals such as lotions, creams, balms, non-aerosol sprays and roll-ons, and ingestibles such as gummies, softgels and tinctures. The facility is able to accommodate on average about 100,000 units/week per one shift.
Bard continued: “Branding and third party production can be hard to find, and even harder to be done right. e2e is a trusted partner; as evidenced by the fact that we’re currently producing products for today’s dominant CBD brands in retail.”
In addition to CBD, e2e also produces non-CBD branded products through its white and private label services, including plant-based and plant-adaptogen health and wellness products, topicals, ingestibles, and beauty products. e2e’s goal is to continue to diversify its client base and manufacture end-to-end product solutions for a wide variety of global brands.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
